Current practice and future directions in the prevention and acute management of migraine (Q37695402)

22 August 2017

1 reference

title

Current practice and future directions in the prevention and acute management of migraine (English)

1 reference

22 August 2017

1 reference

1 reference

Till Sprenger

2

0 references

Peter J. Goadsby

series ordinal

1

object named as

Peter J Goadsby

1 reference

22 August 2017

publication date

1 March 2010

1 reference

22 August 2017

1 reference

22 August 2017

volume

9

1 reference

22 August 2017

issue

3

1 reference

22 August 2017

page(s)

285-298

1 reference

The global burden of disease study: implications for neurology

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

1 reference

7 January 2021

Prevalence and burden of migraine in the United States: data from the American Migraine Study II.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

New appendix criteria open for a broader concept of chronic migraine

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

The International Classification of Headache Disorders, 2nd Edition (ICHD-II)--revision of criteria for 8.2 Medication-overuse headache

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Is medication-overuse headache a distinct biological entity?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

EFNS guideline on the drug treatment of migraine - report of an EFNS task force

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Trigeminal autonomic cephalalgias: diagnosis and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

The 5-HT1-like agonist sumatriptan has a significant effect in chronic tension-type headache

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

The headache of SAH responds to sumatriptan

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Features of medication overuse headache following overuse of different acute headache drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Efficacy of 1,000 mg effervescent acetylsalicylic acid and sumatriptan in treating associated migraine symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Lysine-acetylsalicylic acid in acute migraine attacks

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Efficacy and safety of acetaminophen in the treatment of migraine: results of a randomized, double-blind, placebo-controlled, population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Sumatriptan-naproxen for acute treatment of migraine: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Sumatriptan and naproxen sodium for the acute treatment of migraine

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Naproxen sodium in the treatment of migraine

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

A double-blind, randomized, placebo-controlled, single-dose study of the cyclooxygenase-2 inhibitor, GW406381, as a treatment for acute migraine

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Evaluation of a novel solubilized formulation of ibuprofen in the treatment of migraine headache: a randomized, double-blind, placebo-controlled, dose-ranging study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Efficacy of nonprescription doses of ibuprofen for treating migraine headache. a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Tolfenamic acid rapid release versus sumatriptan in the acute treatment of migraine: comparable effect in a double-blind, randomized, controlled, parallel-group study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Randomized, placebo-controlled trial of rofecoxib in the acute treatment of migraine

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Domperidone plus paracetamol in the treatment of migraine

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Comparison of a fixed combination of domperidone and paracetamol (Domperamol) with sumatriptan 50 mg in moderate to severe migraine: a randomised UK primary care study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

A study to compare oral sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine. The Oral Sumatriptan and Aspirin plus Metoclopramide Comparative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Zolmitriptan versus a combination of acetylsalicylic acid and metoclopramide in the acute oral treatment of migraine: a double-blind, randomised, three-attack study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

A double blind study of metoclopramide in the treatment of migraine attacks

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Treatment of severe, disabling migraine attacks in an over-the-counter population of migraine sufferers: results from three randomized, placebo-controlled studies of the combination of acetaminophen, aspirin, and caffeine

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Efficacy and safety of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain: three double-blind, randomized, placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Caffeine as a risk factor for chronic daily headache: a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Migraine--current understanding and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Ergotamine in the acute treatment of migraine: a review and European consensus

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Ergotamine and dihydroergotamine: history, pharmacology, and efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Bioavailability of dihydroergotamine in man

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

A comparison of subcutaneous sumatriptan and dihydroergotamine nasal spray in the acute treatment of migraine

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

The pharmacology of headache

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Comparison of rizatriptan and other triptans on stringent measures of efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Eletriptan for the treatment of migraine in patients with previous poor response or tolerance to oral sumatriptan

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Almotriptan in migraine patients who respond poorly to oral sumatriptan: a double-blind, randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Rizatriptan Multiple Attack Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Within-patient consistency of response of rizatriptan for treating migraine

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Sumatriptan plus metoclopramide in triptan-nonresponsive migraineurs

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Use of 5-HT1 agonists in pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Distribution and excretion of sumatriptan in human milk

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Migraine in pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Serotonin syndrome complicating migraine pharmacotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Serotonin syndrome associated with triptan monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

More on serotonin syndrome associated with triptan monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Serotonin syndrome and rhabdomyolysis induced by concomitant use of triptans, fluoxetine and hypericum

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Prevalence and characteristics of allodynia in headache sufferers: a population study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Cutaneous allodynia in the migraine population

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Observations on 500 cases of migraine and allied vascular headache

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Defeating migraine pain with triptans: a race against the development of cutaneous allodynia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitization.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Symptoms of cutaneous sensitivity pre-treatment and post-treatment: results from the rizatriptan TAME studies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Early vs. non-early intervention in acute migraine-'Act when Mild (AwM)'. A double-blind, placebo-controlled trial of almotriptan

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Almotriptan and its combination with aceclofenac for migraine attacks: a study of efficacy and the influence of auto-evaluated brush allodynia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Frequent triptan use: observations on safety issues

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

The 'Act when Mild' (AwM) study: a step forward in our understanding of early treatment in acute migraine

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Needle-free subcutaneous sumatriptan (Sumavel DosePro): bioequivalence and ease of use.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Aura in some patients with familial hemiplegic migraine can be stopped by intranasal ketamine.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Pathophysiology of the migraine aura. The spreading depression theory

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Mechanisms of spreading depression and hypoxic spreading depression-like depolarization

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Risk factors for headache recurrence after sumatriptan: a study in 366 migraine patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

TRIPSTAR: prioritizing oral triptan treatment attributes in migraine management

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Serotonin and migraine

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Coronary side-effect potential of current and prospective antimigraine drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Emerging therapies for migraine

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Vasoactive peptide release in the extracerebral circulation of humans during migraine headache

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Calcitonin gene-related peptide antagonists as treatments of migraine and other primary headaches

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Nitric oxide synthase inhibition in migraine

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Pharmacological characterization of the competitive GLUK5 receptor antagonist decahydroisoquinoline LY466195 in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Selective seratonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Randomized, controlled trial of telcagepant for the acute treatment of migraine

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

The CGRP-antagonist, BIBN4096BS does not affect cerebral or systemic haemodynamics in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Calcitonin gene-related peptide (CGRP) antagonists and migraine: is this a new era?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Migraine prevalence, disease burden, and the need for preventive therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Suppression of cortical spreading depression in migraine prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

New insights into migraine pathophysiology

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Topiramate 100 mg/day in migraine prevention: a pooled analysis of double-blind randomised controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Topiramate for migraine prevention in a naturalistic setting: results from an open label, flexible dose study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Long-term migraine prevention with topiramate: open-label extension of pivotal trials.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

When can successful migraine prophylaxis be discontinued?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Obesity, migraine, and chronic migraine: possible mechanisms of interaction

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Long-Term Results of Migraine Prophylaxis with Flunarizine and Beta-Blockers

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

The prophylactic value of propranolol in angina pectoris

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Divalproex sodium: migraine treatment and monitoring

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Divalproex sodium in migraine prophylaxis: a dose-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Topiramate for migraine prevention: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Topiramate in migraine prevention: results of a large controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Efficacy of gabapentin in migraine prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Efficacy and tolerability in migraine prophylaxis of flunarizine in reduced doses: a comparison with propranolol 160 mg daily

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Flunarizine in migraine: a minireview

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Amitriptyline in the prophylaxis of migraine. Effectiveness and relationship of antimigraine and antidepressant effects

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

The efficacy and safety of venlafaxine in the prophylaxis of migraine.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Petasites hybridus root (butterbur) is an effective preventive treatment for migraine

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Randomised double-blind placebo-controlled trial of feverfew in migraine prevention

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis--a double-blind, multicentre, randomized placebo-controlled dose-response study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Efficacy and safety of 6.25 mg t.i.d. feverfew CO2-extract (MIG-99) in migraine prevention--a randomized, double-blind, multicentre, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Verapamil in prophylactic therapy of migraine

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Verapamil in migraine prophylaxis--a five-year review

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Clonidine in migraine prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Double-blind trial of fluoxetine: chronic daily headache and migraine.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Topiramate and triptans revert chronic migraine with medication overuse to episodic migraine

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Utility of topiramate for the treatment of patients with chronic migraine in the presence or absence of acute medication overuse

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Repetitive cortical spreading depression in a gyrencephalic feline brain: inhibition by the novel benzoylamino-benzopyran SB-220453

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

SB-220453, a potential novel antimigraine agent, inhibits nitric oxide release following induction of cortical spreading depression in the anaesthetized cat.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Effects of tonabersat on migraine with aura: a randomised, double-blind, placebo-controlled crossover study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Randomized, double-blind, placebo-controlled, proof-of-concept study of the cortical spreading depression inhibiting agent tonabersat in migraine prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Peripheral nerve stimulation inhibits nociceptive processing: an electrophysiological study in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Occipital afferent activation of second order neurons in the trigeminocervical complex in rat.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Stimulation of the greater occipital nerve induces increased central excitability of dural afferent input

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Central neuromodulation in chronic migraine patients with suboccipital stimulators: a PET study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Peripheral neurostimulation for control of intractable occipital neuralgia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Combined occipital and supraorbital neurostimulation for the treatment of chronic migraine headaches: initial experience

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Neurostimulation in primary headache syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Occipital nerve stimulation for drug-resistant chronic cluster headache: a prospective pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Treatment of medically intractable cluster headache by occipital nerve stimulation: long-term follow-up of eight patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Botulinum toxin in clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Subcutaneous administration of botulinum toxin A reduces formalin-induced pain

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

A randomized, double-blind, placebo controlled study on analgesic effects of botulinum toxin A.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

A lack of antinociceptive or antiinflammatory effect of botulinum toxin A in an inflammatory human pain model

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Botulinum Toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

The effects of Botulinum Toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Botulinum toxin A and the cutaneous nociception in humans: a prospective, double-blind, placebo-controlled, randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Botulinum toxin type A inprophylactic treatment of migraine headaches: a preliminary study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Botulinum toxin as preventive treatment for migraine: a randomized double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Botulinum toxin A in the prophylactic treatment of migraine--a randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

A double-blind, randomized, placebo-controlled comparison of botulinum toxin type a injection sites and doses in the prevention of episodic migraine

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Patent foramen ovale and migraine

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Effect on migraine of closure of cardiac right-to-left shunts to prevent recurrence of decompression illness or stroke or for haemodynamic reasons

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Migraine Intervention With STARFlex Technology (MIST) trial: a prospective, multicenter, double-blind, sham-controlled trial to evaluate the effectiveness of patent foramen ovale closure with STARFlex septal repair implant to resolve refractory migr

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Chronic daily headache: identification of factors associated with induction and transformation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Factors associated with the onset and remission of chronic daily headache in a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Obesity is a risk factor for transformed migraine but not chronic tension-type headache

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Exercise in migraine therapy--is there any evidence for efficacy? A critical review

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Behavioral treatment of migraine: current status and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Efficacy of biofeedback for migraine: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Efficacy of acupuncture for the prophylaxis of migraine: a multicentre randomised controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Acupuncture for patients with migraine: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Double-blind randomized placebo-controlled study of homoeopathic prophylaxis of migraine

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Acupuncture for treating acute attacks of migraine: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Effectiveness of an intensive multidisciplinary headache treatment program

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Behavioral and Pharmacologic Treatment of Transformed Migraine With Analgesic Overuse: Outcome at 3 Years

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Efficacy of multidisciplinary treatment in a tertiary referral headache centre.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Current diagnosis and treatment of migraine

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Transformed migraine and medication overuse in a tertiary headache centre--clinical characteristics and treatment outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Medication-overuse headache: where are we now?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Greater occipital nerve injection in primary headache syndromes--prolonged effects from a single injection

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Prednisone as initial treatment of analgesic-induced daily headache

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Prednisolone does not reduce withdrawal headache: a randomized, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Prednisone vs. placebo in withdrawal therapy following medication overuse headache

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Discontinuation of medication overuse in headache patients: recovery of therapeutic responsiveness.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Orbitofrontal cortex involvement in chronic analgesic-overuse headache evolving from episodic migraine

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

Repetitive intravenous dihydroergotamine as therapy for intractable migraine.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970005-3

7 January 2021

10.1016/S1474-4422(10)70005-3

Identifiers

DOI

1 reference

22 August 2017

1 reference